Health
Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
Early patient data from Phase 2b clinical trial showed significant and selective tumor uptake in brain metastases compared to MRI Phase 2b clinical trial expected to complete enrollment and have topline data in 1H26 SYDNEY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the Phase 2
About this update from Radiopharm Theranostics Limited
[{"type":"image","alt":"Radiopharm Theranostics","displaySize":"","headline":null,"caption":"Radiopharm Theranostics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/89242f226a5af9cc676bf90c10bb0d8b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PqMiWwV7mR9zCwiMw6XzSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/89242f226a5af9cc676bf90c10bb0d8b","width":300,"height":110}},"lazy":false},{"type":"text","content":"Early patient data from Phase 2b clinical trial showed significant and selective tumor uptake in brain metastases compared to MRI","length":129,"tagName":"p"},{"type":"text","content":"Phase 2b clinical trial expected to complete enrollment and have topline data in 1H26","length":85,"tagName":"p"},{"type":"text","content":"SYDNEY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the Phase 2b trial evaluating RAD101 imaging in brain metastases has achieved 50% patient enrollment threshold.","length":384,"tagName":"p"},{"type":"text","content":"“Enrolling 50% of the patients in our Phase 2b study of RAD101 is a meaningful achievement for our RAD101 development program that brings us closer to demonstrating its clinical benefit in distinguishing between tumor recurrence and radiation necrosis in patients with brain metastasis following anticancer treatments, like SRS/radiation,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “Meeting this half-way milestone, along with our continuing momentum in patient enrollment, gives us further confidence in our plans to complete enrollment and share topline results in the first half of 2026.”","length":627,"tagName":"p"},{"type":"text","content":"RAD101 is the Company’s novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors, including Brain metastases.","length":223,"tagName":"p"},{"type":"text","content":"Data from the first three patients showed significant and selective tumor uptake in brain metastases. Ima...